Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial

Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. In a trial with...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The Lancet (British edition) Ročník 375; číslo 9717; s. 824 - 833
Hlavní autori: Lingappa, Jairam R, Baeten, Jared M, Wald, Anna, Hughes, James P, Thomas, Katherine K, Mujugira, Andrew, Mugo, Nelly, Bukusi, Elizabeth A, Cohen, Craig R, Katabira, Elly, Ronald, Allan, Kiarie, James, Farquhar, Carey, Stewart, Grace John, Makhema, Joseph, Essex, Myron, Were, Edwin, Fife, Kenneth H, de Bruyn, Guy, Gray, Glenda E, McIntyre, James A, Manongi, Rachel, Kapiga, Saidi, Coetzee, David, Allen, Susan, Inambao, Mubiana, Kayitenkore, Kayitesi, Karita, Etienne, Kanweka, William, Delany, Sinead, Rees, Helen, Vwalika, Bellington, Magaret, Amalia S, Wang, Richard S, Kidoguchi, Lara, Barnes, Linda, Ridzon, Renee, Corey, Lawrence, Celum, Connie
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Kidlington Elsevier Ltd 06.03.2010
Elsevier
Elsevier Limited
Predmet:
ISSN:0140-6736, 1474-547X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Buďte prvý, kto okomentuje tento záznam!
Najprv sa musíte prihlásiť.